2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-07,CytRx To Present At The 29th Annual ROTH Conference
2017-02-06,CytRx To Present At The 19th Annual BIO CEO & Investor Conference
2017-01-25,First Week of CYTR September 15th Options Trading
2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-19,CytRx Appoints Chief Medical Officer Dr. Daniel Levitt As Chief Operating Officer
2016-12-13,CytRx Corporation Announces $8.1 Million Registered Direct Offering Of Common Stock
2016-12-02,Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board Of Directors
2016-11-29,CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
2016-09-22,24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation
2016-09-22,DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-20,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In CytRx Corporation To Contact The Firm Before Imminent Lead Plaintiff Deadline
2016-09-19,GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm
2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
2016-09-09,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-07,INVESTOR ALERT: Rosen Law Firm Reminds CytRx Corporation Investors Of Important September 23 Deadline In Class Action - CYTR
2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
2016-09-06,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-09-06,CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-31,CYTR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving CytRx Corporation and a Lead Plaintiff Deadline of September 23, 2016
2016-08-26,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-08-26,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-25,Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm
2016-08-22,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-15,Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against CytRx Corporation
2016-08-12,STOCK NOTICE: Rosen Law Firm Reminds CytRx Corporation Investors Of Important Deadline In Class Action
2016-08-11,Robbins Arroyo LLP: CytRx Corporation (CYTR) Misled Shareholders According To A Recently Filed Class Action
2016-08-05,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In CytRx Corporation Of Class Action Lawsuit And Upcoming Deadline - CYTR
2016-08-05,Lifshitz & Miller Law Firm Announces Investigation Of American Renal Associates Holdings, Inc., CytRx Corporation, El Pollo Loco Holdings, Inc., EndoChoice Holdings, Inc., Full Circle Capital Corporation And ZIOPHARM Oncology, Inc.
2016-08-03,INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline
2016-08-03,CytRx Corporation Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2016-08-02,SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against CytRx Corporation (CYTR) And Lead Plaintiff Deadline: September 23, 2016
2016-07-29,CytRx (CYTR) Strong On High Relative Volume Today
2016-07-29,These 5 Stocks Are Poised for Breakouts
2016-07-27,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR
2016-07-25,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-07-20,SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Claims Against CytRx Corporation And Advises Investors With Losses To Contact The Firm
2016-07-18,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-18,Interesting CYTR Put And Call Options For March 2017
2016-07-15,CytRx Corporation Announces Pricing Of $20 Million Public Offering Of Common Stock And Warrants
2016-07-14,SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm
2016-07-14,CytRx Corporation Announces Proposed Public Offering Of Common Stock And Warrants
2016-07-14,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation - CYTR
2016-07-13,Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock
2016-07-12,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CytRx Corporation (CYTR)
2016-07-12,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-11,CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial
2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-31,CytRx To Present At Jefferies 2016 Global Healthcare Conference
2016-05-13,Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted
2016-05-10,CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail
2016-04-28,CytRx To Present At Joseph Gunnar And Co.'s PIONEERS 2016 Investor Conference
2016-04-25,CytRx (CYTR) Flagged As Strong On High Volume
2016-04-25,CytRx And PRA Health Sciences Receive Gold Awards For Excellence In Clinical Research As The Strategic Partnership Team Of The Year
2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
2016-04-18,CYTR December 16th Options Begin Trading
2016-04-18,CytRx (CYTR) Strong On High Relative Volume Today
2016-04-11,CytRx (CYTR) Stock: Weak On High Volume Today
2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
2016-03-22,First Week of May 20th Options Trading For CytRx (CYTR)
2016-03-22,CytRx To Present New Data Using Its Proprietary LADR™ Technology At The 2016 American Association For Cancer Research Annual Meeting
2016-02-29,Interesting CYTR Put And Call Options For April 15th
2016-02-29,CytRx To Present At The Cowen & Company's 36th Annual Health Care Conference
2016-02-12,First Week of September 16th Options Trading For CytRx (CYTR)
2016-02-08,CytRx Secures $40 Million Long-Term Loan Facility
2016-02-01,CytRx To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-11,CytRx Corporation Appoints Olivia Ware As Chief Commercial Officer
2016-01-05,CytRx Announces Settlement Of California Stockholder Derivative Lawsuit
2015-12-10,CytRx Announces Settlement Of The Consolidated Securities Class Action Lawsuit
2015-12-07,CytRx Nominates Next Clinical Drug Candidate DK049
2015-12-03,CytRx Announces Participation At The 26th Annual Oppenheimer Healthcare Conference
2015-12-01,CytRx Announces The Completion Of Enrollment In Pivotal Global Phase 3 Trial Ahead Of Schedule
2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
2015-10-20,First Week of June 2016 Options Trading For CytRx (CYTR)
2015-09-21,CytRx Announces The Publication Of Its Positive Global Phase 2b Clinical Trial Results For Soft Tissue Sarcoma In The Peer-Reviewed JAMA Oncology
2015-09-03,CytRx Announces The Presentation Of Its Phase 2b Clinical Trial Design In Small Cell Lung Cancer At The World Conference On Lung Cancer In Denver, Colorado
2015-09-01,CytRx Announces Participation At FBR & Co. Second Annual Health Conference And Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-13,Short Interest In CytRx Decreases By 10.4%
2015-07-24,CytRx Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-21,CytRx Announces Pricing Of Public Offering Of 9.1 Million Shares Of Common Stock
2015-07-20,CytRx Announces Proposed Public Offering Of Common Stock
2015-06-30,CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform
2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
2015-06-24,Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board Of Directors
2015-06-02,CytRx Announces Settlement Of Stockholder Derivative Lawsuit In Delaware
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
2015-05-26,CytRx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
2015-05-19,First Week Of July 17th Options Trading For CytRx (CYTR)
2015-05-05,CytRx (CYTR) Is Weak On High Volume Today
2015-05-04,CytRx (CYTR) Is Strong On High Volume Today
2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
2015-04-29,CytRx Announces Publication Of Glioblastoma Clinical Case Study In Journal Of Nuclear Medicine & Radiation Therapy
2015-04-21,Interesting CYTR Put And Call Options For December 18th
2015-04-17,CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation
2015-04-17,Strong On High Relative Volume: CytRx (CYTR)
2015-03-11,Dr. Anita J. Chawla Joins CytRx Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology
2015-02-25,CytRx To Present At The Cowen & Company 35th Annual Health Care Conference
2015-02-02,CytRx To Present At The 17th Annual BIO CEO & Investor Conference On February 9, 2015 In New York City
2015-01-23,First Week Of September 18th Options Trading For CYTR
2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
2014-12-02,Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
2014-12-02,CytRx To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
2014-10-30,CytRx Announces Oral Presentation At 2014 Chemotherapy Foundation Symposium
2014-10-29,CytRx Announces Publication Of Preclinical Glioblastoma Data In Neoplasia
2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
2014-10-16,CytRx Appoints Steven A. Kriegsman As Chairman Of The Board
2014-10-13,CytRx Launches Discovery Laboratory To Develop Albumin-Binding Anti-Cancer Drug Platform
2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
2014-10-07,CytRx Announces Unexpected Passing Of Chairman Max Link, PhD
2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
2014-09-26,CytRx Updates Presentation Time At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
2014-09-19,CytRx To Present At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-16,Federman & Sherwood Investigates CytRx Corporation For Possible Violations Of Federal Securities Laws
2014-09-15,Former Louisiana Attorney General And KSF Announce Appointment As Lead Counsel In CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire For More Information
2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
2014-09-05,CytRx Updates Presentation Time At Aegis 2014 Healthcare & Technology Conference
2014-09-02,CytRx To Present At Upcoming Investor Conferences In New York City And Las Vegas
2014-08-28,5 Breakout Stocks Under $10 Set to Soar
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-22,Biotech Stock Mailbag: Threshold, Galena, CytRx
2014-08-11,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
2014-08-06,CytRx Reports 2014 Second Quarter Financial Results
2014-07-09,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-06-30,CytRx Added To Russell 3000&#174; And Russell 2000&#174; Indexes
2014-06-13,5 Stocks Poised for Breakouts
2014-06-06,5 Stocks Poised to Break Out
2014-06-04,3 Stocks Under $10 Moving Higher
2014-05-29,5 Stocks Under $10 Set to Soar
2014-05-29,CytRx To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-14,3 Biotech Stocks Under $10 to Watch
2014-05-09,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against CytRx Corporation And Certain Officers - CYTR
2014-05-06,Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
2014-05-02,Pre-Market Review On Top Gainers -- Research On SouFun Holdings, CytRx, Iridium Communications, And Qihoo 360 Technology
2014-05-01,CytRx Reports 2014 First Quarter Financial Results
2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
2014-04-23,Hagens Berman: 21 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-04-23,Lieff Cabraser Reminds CytRx Corporation Investors Of Upcoming Deadline In Class Action Litigation &#8211; CYTR
2014-04-22,Interesting CYTR Put And Call Options For December 20th
2014-04-15,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The May 13, 2014 Lead Plaintiff Deadline
2014-04-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against CYTRX CORPORATION And Its Board Of Directors And A Lead Plaintiff Deadline Of May 13, 2014 -- CYTR
2014-04-10,CytRx Announces Research And Development Day And Webcast
2014-04-09,Hagens Berman Reminds CytRx Investors Of May 13, 2014 Lead Plaintiff Deadline And Inclusion Of Those Who Purchased Stock From Feb. 5, 2014 Offering
2014-04-04,Technical Update On Active Stocks -- Research On CytRx, FireEye, Yandex, And Hewlett-Packard
2014-04-03,Why CytRx (CYTR) Stock Is Surging Today
2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
2014-04-01,Speculative Biotech Stock Offers Opportunity Amid Controversy
2014-03-31,CORRECTING and REPLACING Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation
2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
2014-03-28,Cohen Milstein Sellers &amp; Toll PLLC Announces The Investigation Of CytRx Corporation
2014-03-27,Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)
2014-03-27,CytRx Issues Statement Regarding Recent Lawsuits
2014-03-26,Interesting CYTR Put And Call Options For May 17th
2014-03-25,These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
2014-03-24,In This Trader's Market, a Week or More Is Now Long Term
2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
2014-03-21,/C O R R E C T I O N -- Robbins Arroyo LLP/
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-07,CytRx To Present At The 29th Annual ROTH Conference
2017-02-06,CytRx To Present At The 19th Annual BIO CEO & Investor Conference
2017-01-25,First Week of CYTR September 15th Options Trading
2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-19,CytRx Appoints Chief Medical Officer Dr. Daniel Levitt As Chief Operating Officer
2016-12-13,CytRx Corporation Announces $8.1 Million Registered Direct Offering Of Common Stock
2016-12-02,Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board Of Directors
2016-11-29,CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
2016-09-22,24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation
2016-09-22,DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-20,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In CytRx Corporation To Contact The Firm Before Imminent Lead Plaintiff Deadline
2016-09-19,GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm
2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
2016-09-09,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-07,INVESTOR ALERT: Rosen Law Firm Reminds CytRx Corporation Investors Of Important September 23 Deadline In Class Action - CYTR
2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
2016-09-06,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-09-06,CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-31,CYTR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving CytRx Corporation and a Lead Plaintiff Deadline of September 23, 2016
2016-08-26,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-08-26,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-25,Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm
2016-08-22,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-15,Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against CytRx Corporation
2016-08-12,STOCK NOTICE: Rosen Law Firm Reminds CytRx Corporation Investors Of Important Deadline In Class Action
2016-08-11,Robbins Arroyo LLP: CytRx Corporation (CYTR) Misled Shareholders According To A Recently Filed Class Action
2016-08-05,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In CytRx Corporation Of Class Action Lawsuit And Upcoming Deadline - CYTR
2016-08-05,Lifshitz & Miller Law Firm Announces Investigation Of American Renal Associates Holdings, Inc., CytRx Corporation, El Pollo Loco Holdings, Inc., EndoChoice Holdings, Inc., Full Circle Capital Corporation And ZIOPHARM Oncology, Inc.
2016-08-03,INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline
2016-08-03,CytRx Corporation Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2016-08-02,SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against CytRx Corporation (CYTR) And Lead Plaintiff Deadline: September 23, 2016
2016-07-29,CytRx (CYTR) Strong On High Relative Volume Today
2016-07-29,These 5 Stocks Are Poised for Breakouts
2016-07-27,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR
2016-07-25,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-07-20,SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Claims Against CytRx Corporation And Advises Investors With Losses To Contact The Firm
2016-07-18,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-18,Interesting CYTR Put And Call Options For March 2017
2016-07-15,CytRx Corporation Announces Pricing Of $20 Million Public Offering Of Common Stock And Warrants
2016-07-14,SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm
2016-07-14,CytRx Corporation Announces Proposed Public Offering Of Common Stock And Warrants
2016-07-14,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation - CYTR
2016-07-13,Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock
2016-07-12,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CytRx Corporation (CYTR)
2016-07-12,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-11,CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial
2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-31,CytRx To Present At Jefferies 2016 Global Healthcare Conference
2016-05-13,Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted
2016-05-10,CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail
2016-04-28,CytRx To Present At Joseph Gunnar And Co.'s PIONEERS 2016 Investor Conference
2016-04-25,CytRx (CYTR) Flagged As Strong On High Volume
2016-04-25,CytRx And PRA Health Sciences Receive Gold Awards For Excellence In Clinical Research As The Strategic Partnership Team Of The Year
2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
2016-04-18,CYTR December 16th Options Begin Trading
2016-04-18,CytRx (CYTR) Strong On High Relative Volume Today
2016-04-11,CytRx (CYTR) Stock: Weak On High Volume Today
2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
2016-03-22,First Week of May 20th Options Trading For CytRx (CYTR)
2016-03-22,CytRx To Present New Data Using Its Proprietary LADR™ Technology At The 2016 American Association For Cancer Research Annual Meeting
2016-02-29,Interesting CYTR Put And Call Options For April 15th
2016-02-29,CytRx To Present At The Cowen & Company's 36th Annual Health Care Conference
2016-02-12,First Week of September 16th Options Trading For CytRx (CYTR)
2016-02-08,CytRx Secures $40 Million Long-Term Loan Facility
2016-02-01,CytRx To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-11,CytRx Corporation Appoints Olivia Ware As Chief Commercial Officer
2016-01-05,CytRx Announces Settlement Of California Stockholder Derivative Lawsuit
2015-12-10,CytRx Announces Settlement Of The Consolidated Securities Class Action Lawsuit
2015-12-07,CytRx Nominates Next Clinical Drug Candidate DK049
2015-12-03,CytRx Announces Participation At The 26th Annual Oppenheimer Healthcare Conference
2015-12-01,CytRx Announces The Completion Of Enrollment In Pivotal Global Phase 3 Trial Ahead Of Schedule
2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
2015-10-20,First Week of June 2016 Options Trading For CytRx (CYTR)
2015-09-21,CytRx Announces The Publication Of Its Positive Global Phase 2b Clinical Trial Results For Soft Tissue Sarcoma In The Peer-Reviewed JAMA Oncology
2015-09-03,CytRx Announces The Presentation Of Its Phase 2b Clinical Trial Design In Small Cell Lung Cancer At The World Conference On Lung Cancer In Denver, Colorado
2015-09-01,CytRx Announces Participation At FBR & Co. Second Annual Health Conference And Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-13,Short Interest In CytRx Decreases By 10.4%
2015-07-24,CytRx Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-21,CytRx Announces Pricing Of Public Offering Of 9.1 Million Shares Of Common Stock
2015-07-20,CytRx Announces Proposed Public Offering Of Common Stock
2015-06-30,CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform
2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
2015-06-24,Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board Of Directors
2015-06-02,CytRx Announces Settlement Of Stockholder Derivative Lawsuit In Delaware
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
2015-05-26,CytRx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
2015-05-19,First Week Of July 17th Options Trading For CytRx (CYTR)
2015-05-05,CytRx (CYTR) Is Weak On High Volume Today
2015-05-04,CytRx (CYTR) Is Strong On High Volume Today
2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
2015-04-29,CytRx Announces Publication Of Glioblastoma Clinical Case Study In Journal Of Nuclear Medicine & Radiation Therapy
2015-04-21,Interesting CYTR Put And Call Options For December 18th
2015-04-17,CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation
2015-04-17,Strong On High Relative Volume: CytRx (CYTR)
2015-03-11,Dr. Anita J. Chawla Joins CytRx Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology
2015-02-25,CytRx To Present At The Cowen & Company 35th Annual Health Care Conference
2015-02-02,CytRx To Present At The 17th Annual BIO CEO & Investor Conference On February 9, 2015 In New York City
2015-01-23,First Week Of September 18th Options Trading For CYTR
2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
2014-12-02,Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
2014-12-02,CytRx To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
2014-10-30,CytRx Announces Oral Presentation At 2014 Chemotherapy Foundation Symposium
2014-10-29,CytRx Announces Publication Of Preclinical Glioblastoma Data In Neoplasia
2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
2014-10-16,CytRx Appoints Steven A. Kriegsman As Chairman Of The Board
2014-10-13,CytRx Launches Discovery Laboratory To Develop Albumin-Binding Anti-Cancer Drug Platform
2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
2014-10-07,CytRx Announces Unexpected Passing Of Chairman Max Link, PhD
2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
2014-09-26,CytRx Updates Presentation Time At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
2014-09-19,CytRx To Present At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-16,Federman & Sherwood Investigates CytRx Corporation For Possible Violations Of Federal Securities Laws
2014-09-15,Former Louisiana Attorney General And KSF Announce Appointment As Lead Counsel In CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire For More Information
2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
2014-09-05,CytRx Updates Presentation Time At Aegis 2014 Healthcare & Technology Conference
2014-09-02,CytRx To Present At Upcoming Investor Conferences In New York City And Las Vegas
2014-08-28,5 Breakout Stocks Under $10 Set to Soar
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-22,Biotech Stock Mailbag: Threshold, Galena, CytRx
2014-08-11,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
2014-08-06,CytRx Reports 2014 Second Quarter Financial Results
2014-07-09,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-06-30,CytRx Added To Russell 3000&#174; And Russell 2000&#174; Indexes
2014-06-13,5 Stocks Poised for Breakouts
2014-06-06,5 Stocks Poised to Break Out
2014-06-04,3 Stocks Under $10 Moving Higher
2014-05-29,5 Stocks Under $10 Set to Soar
2014-05-29,CytRx To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-14,3 Biotech Stocks Under $10 to Watch
2014-05-09,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against CytRx Corporation And Certain Officers - CYTR
2014-05-06,Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
2014-05-02,Pre-Market Review On Top Gainers -- Research On SouFun Holdings, CytRx, Iridium Communications, And Qihoo 360 Technology
2014-05-01,CytRx Reports 2014 First Quarter Financial Results
2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
2014-04-23,Hagens Berman: 21 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-04-23,Lieff Cabraser Reminds CytRx Corporation Investors Of Upcoming Deadline In Class Action Litigation &#8211; CYTR
2014-04-22,Interesting CYTR Put And Call Options For December 20th
2014-04-15,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The May 13, 2014 Lead Plaintiff Deadline
2014-04-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against CYTRX CORPORATION And Its Board Of Directors And A Lead Plaintiff Deadline Of May 13, 2014 -- CYTR
2014-04-10,CytRx Announces Research And Development Day And Webcast
2014-04-09,Hagens Berman Reminds CytRx Investors Of May 13, 2014 Lead Plaintiff Deadline And Inclusion Of Those Who Purchased Stock From Feb. 5, 2014 Offering
2014-04-04,Technical Update On Active Stocks -- Research On CytRx, FireEye, Yandex, And Hewlett-Packard
2014-04-03,Why CytRx (CYTR) Stock Is Surging Today
2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
2014-04-01,Speculative Biotech Stock Offers Opportunity Amid Controversy
2014-03-31,CORRECTING and REPLACING Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation
2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
2014-03-28,Cohen Milstein Sellers &amp; Toll PLLC Announces The Investigation Of CytRx Corporation
2014-03-27,Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)
2014-03-27,CytRx Issues Statement Regarding Recent Lawsuits
2014-03-26,Interesting CYTR Put And Call Options For May 17th
2014-03-25,These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
2014-03-24,In This Trader's Market, a Week or More Is Now Long Term
2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
2014-03-21,/C O R R E C T I O N -- Robbins Arroyo LLP/
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-08,Could These 9 Drugs Gain FDA Approval in the Age of Trump?
2017-03-08,The 'Gnarly 9' Biotechs Will Test the FDA's Mettle
2017-03-07,CytRx To Present At The 29th Annual ROTH Conference
2017-02-06,CytRx To Present At The 19th Annual BIO CEO & Investor Conference
2017-01-25,First Week of CYTR September 15th Options Trading
2017-01-04,CytRx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin As A Treatment For Patients With Relapsed Soft Tissue Sarcomas
2016-12-22,What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
2016-12-19,CytRx Appoints Chief Medical Officer Dr. Daniel Levitt As Chief Operating Officer
2016-12-13,CytRx Corporation Announces $8.1 Million Registered Direct Offering Of Common Stock
2016-12-02,Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board Of Directors
2016-11-29,CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA
2016-11-15,Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive
2016-11-11,CytRx Presents Positive Interim Results From On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial At The 2016 CTOS Annual Meeting
2016-10-10,CytRx Presents Interim Results From On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial At ESMO 2016 Congress
2016-09-22,24-Hour Deadline Alert: Law Offices Of Howard G. Smith Reminds Investors Of The Upcoming September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation
2016-09-22,DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-20,SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In CytRx Corporation To Contact The Firm Before Imminent Lead Plaintiff Deadline
2016-09-19,GPM Reminds Investors Of The September 23rd Deadline In The Class Action Lawsuit Against CytRx Corporation And Encourages Investors To Contact The Firm
2016-09-12,CytRx To Present Data At The European Society For Medical Oncology 2016 Congress From Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial
2016-09-09,INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016 - CYTR
2016-09-07,INVESTOR ALERT: Rosen Law Firm Reminds CytRx Corporation Investors Of Important September 23 Deadline In Class Action - CYTR
2016-09-07,CytRx Announces the Completion of Enrollment in Its Global Phase 2b Clinical Trial of Aldoxorubicin in Patients with Second-Line Small Cell Lung Cancer
2016-09-06,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-09-06,CytRx to Present at the Rodman & Renshaw 18th Annual Global Investment Conference
2016-08-31,CYTR INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving CytRx Corporation and a Lead Plaintiff Deadline of September 23, 2016
2016-08-26,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-08-26,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of CytRx Corporation Of Commencement Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-25,Brower Piven Alerts Shareholders Of Upcoming Deadline In Class Action Lawsuit And Encourages Those With Losses From Investment In CytRx Corporation To Contact The Firm
2016-08-22,CYTR SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving CytRx Corporation And A Lead Plaintiff Deadline Of September 23, 2016
2016-08-15,Federman & Sherwood Reminds Investors Of Imminent Lead Plaintiff Deadline In Securities Class Action Lawsuit Against CytRx Corporation
2016-08-12,STOCK NOTICE: Rosen Law Firm Reminds CytRx Corporation Investors Of Important Deadline In Class Action
2016-08-11,Robbins Arroyo LLP: CytRx Corporation (CYTR) Misled Shareholders According To A Recently Filed Class Action
2016-08-05,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders With Losses On Their Investment In CytRx Corporation Of Class Action Lawsuit And Upcoming Deadline - CYTR
2016-08-05,Lifshitz & Miller Law Firm Announces Investigation Of American Renal Associates Holdings, Inc., CytRx Corporation, El Pollo Loco Holdings, Inc., EndoChoice Holdings, Inc., Full Circle Capital Corporation And ZIOPHARM Oncology, Inc.
2016-08-03,INVESTOR ALERT: Brower Piven Notifies Shareholders Of Securities Class Action Lawsuit And Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The Lead Plaintiff Deadline
2016-08-03,CytRx Corporation Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors
2016-08-02,SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors Of Class Action Against CytRx Corporation (CYTR) And Lead Plaintiff Deadline: September 23, 2016
2016-07-29,CytRx (CYTR) Strong On High Relative Volume Today
2016-07-29,These 5 Stocks Are Poised for Breakouts
2016-07-27,EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CytRx Corporation - CYTR
2016-07-25,Glancy Prongay & Murray Announces The Filing Of A Securities Class Action On Behalf Of CytRx Corporation Investors And Encourages Investors To Contact The Firm
2016-07-20,SHAREHOLDER ALERT: Goldberg Law PC Announces An Investigation Of Claims Against CytRx Corporation And Advises Investors With Losses To Contact The Firm
2016-07-18,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-18,Interesting CYTR Put And Call Options For March 2017
2016-07-15,CytRx Corporation Announces Pricing Of $20 Million Public Offering Of Common Stock And Warrants
2016-07-14,SHAREHOLDER NOTICE: Khang & Khang LLP Announces An Investigation Of CytRx Corporation And Reminds Investors With Losses To Contact The Firm
2016-07-14,CytRx Corporation Announces Proposed Public Offering Of Common Stock And Warrants
2016-07-14,INVESTOR ALERT: Levi & Korsinsky, LLP Announces An Investigation Concerning Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation - CYTR
2016-07-13,Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock
2016-07-12,SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of CytRx Corporation (CYTR)
2016-07-12,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces An Investigation Involving Possible Violations Of Federal Securities Laws By Certain Officers And Directors Of CytRx Corporation
2016-07-11,CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial
2016-07-11,CytRx Announces Initial Results Of Phase 3 Trial Of Aldoxorubicin In Patients With Second-Line Soft Tissue Sarcoma; Subsequent Analysis To Be Announced Fourth Quarter 2016
2016-06-06,CytRx Presents Updated Aldoxorubicin Clinical Trial Results At The 2016 American Society Of Clinical Oncology Annual Meeting
2016-05-31,CytRx To Present At Jefferies 2016 Global Healthcare Conference
2016-05-13,Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted
2016-05-10,CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail
2016-04-28,CytRx To Present At Joseph Gunnar And Co.'s PIONEERS 2016 Investor Conference
2016-04-25,CytRx (CYTR) Flagged As Strong On High Volume
2016-04-25,CytRx And PRA Health Sciences Receive Gold Awards For Excellence In Clinical Research As The Strategic Partnership Team Of The Year
2016-04-20,CytRx To Present Updated Aldoxorubicin Clinical Trial Data At The American Society Of Clinical Oncology Annual Meeting In June 2016
2016-04-18,CYTR December 16th Options Begin Trading
2016-04-18,CytRx (CYTR) Strong On High Relative Volume Today
2016-04-11,CytRx (CYTR) Stock: Weak On High Volume Today
2016-04-04,CytRx Global Pivotal Phase 3 Clinical Trial With Aldoxorubicin Achieves 191 Target Events Triggering Statistical Data Analysis
2016-03-22,First Week of May 20th Options Trading For CytRx (CYTR)
2016-03-22,CytRx To Present New Data Using Its Proprietary LADR™ Technology At The 2016 American Association For Cancer Research Annual Meeting
2016-02-29,Interesting CYTR Put And Call Options For April 15th
2016-02-29,CytRx To Present At The Cowen & Company's 36th Annual Health Care Conference
2016-02-12,First Week of September 16th Options Trading For CytRx (CYTR)
2016-02-08,CytRx Secures $40 Million Long-Term Loan Facility
2016-02-01,CytRx To Present At The 18th Annual BIO CEO & Investor Conference
2016-01-11,CytRx Corporation Appoints Olivia Ware As Chief Commercial Officer
2016-01-05,CytRx Announces Settlement Of California Stockholder Derivative Lawsuit
2015-12-10,CytRx Announces Settlement Of The Consolidated Securities Class Action Lawsuit
2015-12-07,CytRx Nominates Next Clinical Drug Candidate DK049
2015-12-03,CytRx Announces Participation At The 26th Annual Oppenheimer Healthcare Conference
2015-12-01,CytRx Announces The Completion Of Enrollment In Pivotal Global Phase 3 Trial Ahead Of Schedule
2015-11-23,Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial
2015-10-28,CytRx To Present Additional Data From Its Phase 1b/2 Clinical Trial Combining Aldoxorubicin With Ifosfamide/Mesna At The CTOS 2015 Annual Meeting
2015-10-20,First Week of June 2016 Options Trading For CytRx (CYTR)
2015-09-21,CytRx Announces The Publication Of Its Positive Global Phase 2b Clinical Trial Results For Soft Tissue Sarcoma In The Peer-Reviewed JAMA Oncology
2015-09-03,CytRx Announces The Presentation Of Its Phase 2b Clinical Trial Design In Small Cell Lung Cancer At The World Conference On Lung Cancer In Denver, Colorado
2015-09-01,CytRx Announces Participation At FBR & Co. Second Annual Health Conference And Rodman & Renshaw 17th Annual Global Investment Conference
2015-08-13,Short Interest In CytRx Decreases By 10.4%
2015-07-24,CytRx Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares
2015-07-21,CytRx Announces Pricing Of Public Offering Of 9.1 Million Shares Of Common Stock
2015-07-20,CytRx Announces Proposed Public Offering Of Common Stock
2015-06-30,CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform
2015-06-29,CytRx Announces Presentation Of Interim Phase 2 Data For Aldoxorubicin For HIV-Related Kaposi's Sarcoma
2015-06-24,Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board Of Directors
2015-06-02,CytRx Announces Settlement Of Stockholder Derivative Lawsuit In Delaware
2015-05-29,Fly Watch: Several Names That May Move Following ASCO Meeting
2015-05-27,CytRx To Present Aldoxorubicin Clinical Data At The 2015 ASCO Annual Meeting
2015-05-26,CytRx To Present At The Jefferies 2015 Global Healthcare Conference
2015-05-21,CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results In Glioblastoma Multiforme (Brain Cancer)
2015-05-19,First Week Of July 17th Options Trading For CytRx (CYTR)
2015-05-05,CytRx (CYTR) Is Weak On High Volume Today
2015-05-04,CytRx (CYTR) Is Strong On High Volume Today
2015-05-04,CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage And Improved Quality Of Life In Chemotherapy Resistant Cancers
2015-04-29,CytRx Announces Publication Of Glioblastoma Clinical Case Study In Journal Of Nuclear Medicine & Radiation Therapy
2015-04-21,Interesting CYTR Put And Call Options For December 18th
2015-04-17,CytRx (CYTR) Stock Rises Today Following Oppenheimer Coverage Initiation
2015-04-17,Strong On High Relative Volume: CytRx (CYTR)
2015-03-11,Dr. Anita J. Chawla Joins CytRx Board Of Directors To Add Additional Drug Commercialization Expertise In Oncology
2015-02-25,CytRx To Present At The Cowen & Company 35th Annual Health Care Conference
2015-02-02,CytRx To Present At The 17th Annual BIO CEO & Investor Conference On February 9, 2015 In New York City
2015-01-23,First Week Of September 18th Options Trading For CYTR
2015-01-22,CytRx Announces Overall Survival Results From Its Global Phase 2b Clinical Trial Of Aldoxorubicin In Soft Tissue Sarcoma
2015-01-20,CytRx Announces FDA's Removal Of Partial Clinical Hold For Aldoxorubicin Clinical Trials Permitting Immediate Enrollment Of New Patients
2015-01-08,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results As A Treatment For HIV-Related Kaposi's Sarcoma (KS)
2015-01-06,CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results In Glioblastoma Multiforme (Brain Cancer)
2014-12-15,Nominees for Absolute Worst Biotechnology CEOs of 2014 Are ...
2014-12-03,CytRx Receives Written FDA Communication Regarding Partial Clinical Hold For Aldoxorubicin Clinical Trials
2014-12-02,Five Biotech Firms Whose Stock-Promoting Efforts Didn't Pay Off
2014-12-02,CytRx To Present At The Oppenheimer 25th Annual Healthcare Conference
2014-11-18,CytRx Announces Partial Clinical Hold Affecting Aldoxorubicin Clinical Trials
2014-10-30,CytRx Announces Oral Presentation At 2014 Chemotherapy Foundation Symposium
2014-10-29,CytRx Announces Publication Of Preclinical Glioblastoma Data In Neoplasia
2014-10-20,CytRx Announces Publication Of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society
2014-10-17,CytRx To Present Data From Global Phase 2b Clinical Trial Of Aldoxorubicin In First-Line Soft Tissue Sarcoma At 2014 CTOS Annual Meeting
2014-10-16,CytRx Appoints Steven A. Kriegsman As Chairman Of The Board
2014-10-13,CytRx Launches Discovery Laboratory To Develop Albumin-Binding Anti-Cancer Drug Platform
2014-10-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Gemcitabine In Patients With Metastatic Solid Tumors
2014-10-07,CytRx Announces Unexpected Passing Of Chairman Max Link, PhD
2014-09-30,CytRx Initiates Global Phase 2b Clinical Trial Of Aldoxorubicin For The Treatment Of Relapsed/Refractory Small Cell Lung Cancer
2014-09-29,CytRx Receives Multiple FDA Orphan Drug Designations For Aldoxorubicin For The Treatment Of Glioblastoma, Small Cell Lung Cancer And Ovarian Cancer
2014-09-26,CytRx Updates Presentation Time At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-22,CytRx Announces Presentation Of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas And Global Phase 2b Small Cell Lung Cancer Trial Designs At ESMO 2014 Congress
2014-09-19,CytRx To Present At BioCentury's 2014 NewsMakers In The Biotech Industry Conference
2014-09-16,Federman & Sherwood Investigates CytRx Corporation For Possible Violations Of Federal Securities Laws
2014-09-15,Former Louisiana Attorney General And KSF Announce Appointment As Lead Counsel In CytRx Securities Fraud Lawsuit: Secondary Offering Shareholders (January 31, 2014) Should Inquire For More Information
2014-09-09,CytRx Initiates Phase 1b Clinical Trial With Combination Of Aldoxorubicin And Ifosfamide/Mesna As First-Line Treatment In Patients With Advanced Sarcomas
2014-09-05,CytRx Updates Presentation Time At Aegis 2014 Healthcare & Technology Conference
2014-09-02,CytRx To Present At Upcoming Investor Conferences In New York City And Las Vegas
2014-08-28,5 Breakout Stocks Under $10 Set to Soar
2014-08-27,4 Under-$10 Biotech Stocks in Breakout Territory
2014-08-22,Biotech Stock Mailbag: Threshold, Galena, CytRx
2014-08-11,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-08-07,Oral Presentation Of CytRx’s Aldoxorubicin Phase 2b Clinical Trial In Soft Tissue Sarcoma Highlighted In The Lancet Oncology
2014-08-06,CytRx Reports 2014 Second Quarter Financial Results
2014-07-09,SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into CytRx Corporation Regarding Possible Breaches Of Fiduciary Duty
2014-06-30,CytRx Added To Russell 3000&#174; And Russell 2000&#174; Indexes
2014-06-13,5 Stocks Poised for Breakouts
2014-06-06,5 Stocks Poised to Break Out
2014-06-04,3 Stocks Under $10 Moving Higher
2014-05-29,5 Stocks Under $10 Set to Soar
2014-05-29,CytRx To Present At The Jefferies 2014 Global Healthcare Conference
2014-05-28,CytRx Highlights Aldoxorubicin Data From Its Global Phase 2b Clinical Trial In First-Line Soft Tissue Sarcoma
2014-05-22,5 Stocks Under $10 Set to Soar
2014-05-14,3 Biotech Stocks Under $10 to Watch
2014-05-09,SHAREHOLDER ALERT: Pomerantz Law Firm Announces The Filing Of A Class Action Against CytRx Corporation And Certain Officers - CYTR
2014-05-06,Hagens Berman: 7 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-05-05,CytRx Reports Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma
2014-05-02,Pre-Market Review On Top Gainers -- Research On SouFun Holdings, CytRx, Iridium Communications, And Qihoo 360 Technology
2014-05-01,CytRx Reports 2014 First Quarter Financial Results
2014-04-28,CytRx To Present Completed Phase 1b/2 Progression-Free Survival And Overall Survival Aldoxorubicin Data In Second-Line Soft Tissue Sarcoma At Upcoming Research And Development Day
2014-04-24,CytRx Announces Global Phase 2b Trial Of Aldoxorubicin In Soft Tissue Sarcomas Selected For Oral Presentation At The 2014 ASCO Annual Meeting
2014-04-23,Hagens Berman: 21 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action
2014-04-23,Lieff Cabraser Reminds CytRx Corporation Investors Of Upcoming Deadline In Class Action Litigation &#8211; CYTR
2014-04-22,Interesting CYTR Put And Call Options For December 20th
2014-04-15,SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In CytRx Corporation To Contact Brower Piven Before The May 13, 2014 Lead Plaintiff Deadline
2014-04-11,SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors Of Class Action Against CYTRX CORPORATION And Its Board Of Directors And A Lead Plaintiff Deadline Of May 13, 2014 -- CYTR
2014-04-10,CytRx Announces Research And Development Day And Webcast
2014-04-09,Hagens Berman Reminds CytRx Investors Of May 13, 2014 Lead Plaintiff Deadline And Inclusion Of Those Who Purchased Stock From Feb. 5, 2014 Offering
2014-04-04,Technical Update On Active Stocks -- Research On CytRx, FireEye, Yandex, And Hewlett-Packard
2014-04-03,Why CytRx (CYTR) Stock Is Surging Today
2014-04-03,CytRx To Present Updated Aldoxorubicin Preclinical Glioblastoma Study Results At The 2014 AACR Annual Meeting
2014-04-01,Speculative Biotech Stock Offers Opportunity Amid Controversy
2014-03-31,CORRECTING and REPLACING Hagens Berman Reminds CytRx Investors of May 13, 2014 Lead Plaintiff Deadline and Continued Securities Fraud Investigation
2014-03-31,CytRx Receives Orphan Medicinal Product Designation From The European Commission For Aldoxorubicin In Soft Tissue Sarcoma
2014-03-28,Cohen Milstein Sellers &amp; Toll PLLC Announces The Investigation Of CytRx Corporation
2014-03-27,Today's Dead Cat Bounce Stock: CytRx Corporation (CYTR)
2014-03-27,CytRx Issues Statement Regarding Recent Lawsuits
2014-03-26,Interesting CYTR Put And Call Options For May 17th
2014-03-25,These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'
2014-03-24,In This Trader's Market, a Week or More Is Now Long Term
2014-03-24,CytRx Initiates Pivotal Global Phase 3 Clinical Trial With Aldoxorubicin For Second-Line Treatment Of Soft Tissue Sarcoma
2014-03-21,/C O R R E C T I O N -- Robbins Arroyo LLP/
